Clinion’s transformative platform is reshaping clinical trials, illustrating how advanced technology is expediting the journey of new therapies to market.
The precision functional genomics company OncoDxRx unveiled its proprietary OncoMRD assay for monitoring residual disease, an advanced "personalized gene signature” designed for high-precision, simultaneous detection of critical tumor and non-tumor biomarkers.
On November 14, 2024, Huijia Health Corporation will deliver a special speech at the MEDICA INNOVATION FORUM (Hall 13, E63) at Medica in Düsseldorf, Germany, from 11:15 to 11:25 am. The speech will focus on Huijia’s groundbreaking nFOPT® Non-invasive Fiber Optic Physiological Monitoring Technology to health management for all ages.
Some patients who receive targeted drugs or immunotherapy experience significant benefit in terms of tumor shrinkage and longer survival as responders — but many do not (i.e., non-responders). A new study suggests that measuring overactive genes in the blood could help doctors determine which drugs are most likely to benefit individual non-responders.
Martine Rothblatt's United Therapeutics and Robinson Helicopter team up to build hydrogen helicopters to deliver organs with zero-carbon eVTOL flights.
OncoDxRx, a California-based liquid biopsy startup, builds gene expression-powered treatment selection technology that helps clinicians identify the most suitable drugs for individual patients who are not responding to current therapies.
Clinion, a Lifescience technology company based out of the US, UK and India, has won a category award in the 2024 Clinical Trials Arena Excellence Awards.
OncoDxRx announced a new cfmRNA-based MRD assay creatively named OncoMRD (OncoDxRx’s monitoring residual disease), which the company said is based on its in-service patient-derived gene expression signature.
Satisfied Users & 
Approved Press Releases
